Stock Price
95.67
Daily Change
0.48 0.50%
Monthly
-1.29%
Yearly
46.51%
Q2 Forecast
93.39

Incyte reported $1.81 in EPS Earnings Per Share for its fiscal quarter ending in March of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q1 Mar/2026 1.81 1.42 1.16 Apr/28
FY2025Q4 Dec/2025 1.80 1.93 1.43 Feb/10
FY2025Q3 Sep/2025 2.26 1.58 1.07 Oct/28
FY2025Q2 Jun/2025 1.57 1.40 -1.82 Jul/29
FY2025Q1 Mar/2025 1.16 1.01 0.64 Apr/29




Eps Change Date
Acadia Pharmaceuticals USD 0.02 1.58 Mar/2026
Agenus USD -0.3 0.84 Dec/2025
Agios Pharmaceuticals USD -1.69 0.17 Mar/2026
Alnylam Pharmaceuticals USD 1.99 0.74 Mar/2026
Amgen USD 5.15 0.14 Mar/2026
BioCryst Pharmaceuticals USD 1.17 1.1 Dec/2025
Biogen USD 3.57 1.58 Mar/2026
BioMarin Pharmaceutical USD 0.76 0.3 Mar/2026
Bristol-Myers Squibb USD 1.58 0.32 Mar/2026
Eli Lilly USD 8.55 1.01 Mar/2026
Exelixis USD 0.87 0.1 Mar/2026
Gilead Sciences USD 2.03 0.17 Mar/2026
Incyte USD 1.81 0.01 Mar/2026
Ionis Pharmaceuticals USD -0.56 0.85 Mar/2026
MacroGenics USD -0.58 0.36 Mar/2026
Merck USD -1.28 3.32 Mar/2026
Moderna USD -3.4 1.29 Mar/2026
Nektar Therapeutics USD -1.35 1.17 Dec/2025
Neurocrine Biosciences USD 1.94 0.06 Mar/2026
Novartis USD 1.99 0.04 Mar/2026
Novartis USD 1.99 0.45 Mar/2026
Pfizer USD 0.75 0.09 Mar/2026
PTC Therapeutics USD -0.03 1.64 Mar/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 9.47 1.97 Mar/2026
Sarepta Therapeutics USD 3.16 6.74 Mar/2026
Ultragenyx Pharmaceutical USD -1.84 0.55 Mar/2026
Vertex Pharmaceuticals USD 4.47 0.56 Mar/2026